Meta-analysis shows methadone exposure linked to higher NAS incidence and treatment needs versus buprenorphine in pregnant women
This systematic review and meta-analysis examined the outcomes of buprenorphine-based therapies versus methadone in pregnant women with opioid use disorder. The pooled analysis included 5524 participants and assessed neonatal abstinence syndrome incidence, pharmacologic treatment for NAS, and birth weight as primary and secondary outcomes. The study did not report adverse events, discontinuations, or tolerability data.
Regarding neonatal abstinence syndrome, infants exposed to methadone demonstrated a higher incidence compared with those exposed to buprenorphine-naloxone. The effect size was 0.44 with a 95% CI of 0.25-0.75 and a P value less than 0.01. Similarly, infants exposed to methadone required more pharmacologic treatment for NAS than those exposed to buprenorphine-naloxone, though the specific effect size for this outcome was not reported.
For birth weight, infants exposed to buprenorphine showed slightly higher weights than those exposed to methadone. The effect size was 0.17 kg with a 95% CI of -0.14 to 1.49 and a P value of 0.049. The authors caution that while these findings suggest potential benefits of buprenorphine-based therapies, the lack of reported safety data and the observational nature of some underlying studies limit definitive conclusions regarding long-term outcomes or rare adverse events.